Investor profile
SOSV
Venture investor that runs the IndieBio life-science program. Participated in Ten63 Therapeutics' 2023 Series A after the company went through IndieBio's 2019 class.
Venture fund
Directory portfolio
Companies connected here
2
Latest company funding first, including rounds involving other investors. Unknown dates last.
Ten63 Therapeutics
Latest company funding · Feb 19, 2026
AI platform for cancer drug discovery
Hoofprint Biome
Latest company funding · Apr 29, 2025
Cattle microbiome engineering company developing probiotics and enzymes to reduce methane and improve yield.
Portfolio coverage reflects public company-investor links tracked in this directory and may not represent the investor's full portfolio.